Aditya Birla Capital Ltd., Cipla Ltd., Swiggy Ltd., NTPC Ltd., ITC Ltd. and Hyundai Motor India Ltd. are among the top names that will announce their quarterly results on Thursday.
Cipla is likely to clock a rise in net profit to Rs 1,345.6 crore and a revenue of Rs 7,438.5 crore for the quarter ended September, according to a survey of analysts' estimates done by Bloomberg.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
ITC will also be reporting its results for the second quarter of fiscal 2026. The company is likely to report a net profit of Rs 21,152.8 crore and revenue of Rs 81,392.6 crore, according to estimates.
Here are what analysts are expecting from these major names:
ITC Q2 Preview: Key Highlights (Cons, YoY)
FMCG heavyweight ITC Ltd. is set to announce its financial results for the September quarter on Thursday. Brokerages remain broadly constructive on ITC, driven by steady cigarette demand and gradual improvement in the FMCG business.
Brokerages expect commentary from FMCG companies to centre on the extent of GST-related trade disruption and its impact on volumes, particularly in rural markets. Analysts say demand normalisation, margin trends amid stable input costs, and early festive-season indicators will be key to assessing the recovery trajectory.
Pharma Q2FY26 Preview
Brokerages expect soft growth in Q2FY26 for pharma companies as waning gRevlimid sales, a weak acute season in India, and GST-related de-stocking weigh on growth.
Revenue growth is projected between 7–10% YoY, while earnings may rise only 4–5%, reflecting margin pressure.
Key Headwinds
Fading gRevlimid Opportunity: Lower US sales of gRevlimid are a major drag for Dr. Reddy's, Zydus, Aurobindo, and Cipla.
GST Impact in India: Channel de-stocking in September 2025 post-GST revision hit billing for 15–20 days.
Weak Acute Season: Slower demand for acute therapies further curbed growth.
Margin Pressure: JM Financial expects low 20% EBITDA margins; ICICI Securities projects 25% margin for coverage companies.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.